How Has The Pruritus Therapeutics Market Size Evolved In Recent Years?
The pruritus therapeutics market has seen considerable growth due to a variety of factors.
•The market size of pruritus therapeutics has seen significant growth in the past few years. The market is set to expand from a size of $11.89 billion in 2024 to $12.51 billion in 2025, indicating a compound annual growth rate (CAGR) of 5.3%.
This surge in the historical period can be traced back to an increase in the occurrence of pruritus, a variety of causes and conditions, a growing older population, and an emphasis on improving patient quality of life.
What Is The Projected Growth Of The Pruritus Therapeutics Market?
The pruritus therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the pruritus therapeutics market is predicted to experience significant growth, expanding to a value of $16.05 billion by 2029 with a compound annual growth rate (CAGR) of 6.4%.
This growth projection for the forecast period is driven by several factors such as increased understanding of pruritus pathophysiology, the development of innovative drug formulations and delivery systems, a focus on personalized medicine, a surge in dermatological research and development, heightened awareness and diagnosis rates, along with a growing interest in herbal and botanical remedies. The forecast period is also expected to see major developments such as the creation of specific itch-receptor agonists and antagonists, market focus on individualized therapeutic strategies, the incorporation of technology in pruritus monitoring and intervention, and partnerships for interdisciplinary research.
What Are The Key Drivers Fueling Growth In The Pruritus Therapeutics Market?
The anticipated upswing in dermatological conditions is projected to drive the expansion of the pruritus therapeutics market. These dermatological conditions encompass skin, hair, nail, and mucous membrane diseases varying from acne and eczema to skin cancer and fungal infections. The specific cause of itching typically determines the administration of pruritus treatments for such skin disorders. The treatments utilized include topical therapies, emollients and moisturizers, immunosuppressive drugs, and medications to treat itching. For instance, the American Cancer Society, a US-based nonprofit with a mission to eradicate cancer, forecasted 108,270 cases of skin cancer in January 2024. This figure signifies a 3.2% growth from the 104,930 case count reported in 2023. Thus, the escalating prevalence of dermatological conditions is steering the pruritus therapeutics market's growth.
What Are The Principal Market Segments In The Global Pruritus Therapeutics Industry?
The pruritus therapeutics market covered in this report is segmented –
1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products
2) By Route Of Administration: Oral, Parenteral, Topical
3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types
4) By End-User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids
2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines
3) By Local Anesthetics: Topical Local Anesthetics
4) By Counterirritants: Menthol-Based Products, Camphor-Based Products
5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants
6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream
7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies
Pre-Book The Pruritus Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Pruritus Therapeutics Sector?
Prime corporations active in the pruritus therapeutics market are concentrating on creating bespoke treatments for uncommon ailments and specific patient groups, including non-systemic ileal bile acid transport inhibitors. This novel approach focuses on addressing the unfulfilled medical demands with individualized medicine. A non-systemic ileal bile acid transport suppressor is a unique medication designed to target bile acid absorption in the intestines while reducing possible system-wide side effects. For example, in June 2023, the France-based pharmaceutical company, Ipsen, gained approval for Bylvay (odevixibat) from the U.S Food and Drug Administration (FDA), a federal department under the Health and Human Services. This medication is designed to address cholestatic pruritus in patients as young as 12 months with Alagille syndrome (ALGS). Bylvay, taken once daily, has minimal exposure to the systemic circulation and is the first medicine authorized in the U.S to treat cholestatic pruritus stemming from progressive familial intrahepatic cholestasis (PFIC). Earlier, Bylvay had received approval in Europe for PFIC treatment and is currently accessible via prescription for suitable ALGS patients.
Who Are the Key Players in the Pruritus Therapeutics Market?
Major companies operating in the pruritus therapeutics market include:
• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Bausch Health Companies Inc.
• Galderma Laboratories LP
• Cipla Limited
• LEO Pharma AS
• Cara Therapeutics Inc.
• GlaxoSmithKline Plc
• Novan Inc.
• Escient Pharmaceuticals Inc.
• Nerre Therapeutic Ltd.
• EPI Health LLC
• Trevi Therapeutics Inc.
• Evelo Biosciences
• Toray Medical Co. Ltd.
What are the Regional Insights into the Pruritus Therapeutics Market?
North America was the largest region in the pruritus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
